Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced that indoximod, its investigational drug candidate, was granted orphan-drug designation by the U.
In a research report issued today, Cantor analyst Daniel Brims reiterated a Buy rating on Merrimack Pharmaceuticals (NASDAQ:MACK) with a $16 price target, following …
